On 23 June 2025, Eli Lilly presented Phase IIb clinical data for bimagrumab in weight loss. After 72 weeks of treatment, the bimagrumab group achieved a 10.8% reduction in body weight, with 100% of the loss coming from fat and a 2.5% increase in muscle mass. The semaglutide group showed a 15.7% weight reduction, but only 71.5% was from fat, with a 7.4% muscle loss. The combination therapy group achieved a 22.1% weight loss, with 92.9% from fat and only a 2.9% muscle loss.

Metabolic indicators revealed that the combination group lost more visceral fat, with significant reductions in inflammatory biomarkers such as hsCRP, as well as greater improvements in triglycerides and blood lipids. The bimagrumab group showed increased LDL, while the combination group had a slight rise that gradually returned to baseline. In terms of safety, common side effects included muscle cramps, diarrhoea and acne, with temporary elevations in ALT and lipase observed early in treatment.

Bimagrumab is an ActRIIA/B antibody, with an affinity of 1.73 pM for ActRIIB and 434 pM for ActRIIA. The ActRII target has achieved preliminary proof of concept for fat loss and muscle gain. Lilly plans to advance bimagrumab into Phase III trials soon, heralding a new era of high-quality weight loss therapies.

Source:
https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247527702&idx=2&sn=26ff89e42d92b981922b55ea225aefa0